{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:47:07Z","timestamp":1762418827239,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.remnie.2021.03.016","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T16:21:18Z","timestamp":1622046078000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation between brain glucose metabolism (18F-FDG) and cerebral blood flow with amyloid tracers (18F-Florbetapir) in clinical routine: Preliminary evidences"],"prefix":"10.1016","volume":"41","author":[{"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Premi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Peli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Camoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Turrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vince D.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Rodella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Magoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Paghera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2021.03.016_bib0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.remnie.2021.03.016_bib0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Demen"},{"key":"10.1016\/j.remnie.2021.03.016_bib0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.remnie.2021.03.016_bib0020","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and 18 F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias","volume":"19","author":"Chetelat","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.remnie.2021.03.016_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-981-32-9358-8_18","article-title":"Tau PET imaging","volume":"1184","author":"Higuchi","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.remnie.2021.03.016_bib0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","article-title":"PET imaging of amyloid in Alzheimer\u2019s disease","volume":"3","author":"Nordberg","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.remnie.2021.03.016_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1212\/WNL.0b013e3181e620f4","article-title":"Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept","volume":"75","author":"Roe","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.remnie.2021.03.016_bib0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/aws327","article-title":"Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer\u2019s disease","volume":"136","author":"Lehmann","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.remnie.2021.03.016_bib0045","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00259-015-3098-2","article-title":"A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives","volume":"42","author":"Morbelli","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2021.03.016_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fnagi.2011.00010","article-title":"Combined imaging markers dissociate Alzheimer\u2019s disease and frontotemporal lobar degeneration \u2014 an ALE meta-analysis","volume":"3","author":"Schroeter","year":"2011","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1016\/j.remnie.2021.03.016_bib0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2967\/jnumed.110.083683","article-title":"Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh Compound B","volume":"52","author":"Meyer","year":"2011","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.remnie.2021.03.016_bib0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.112.107185","article-title":"PET quantification of 18F-florbetaben binding to \u03b2-amyloid deposits in human brains","volume":"54","author":"Becker","year":"2013","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.remnie.2021.03.016_bib0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00259-014-2970-9","article-title":"Current status and future role of brain PET\/MRI in clinical and research settings","volume":"42","author":"Werner","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.remnie.2021.03.016_bib0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.remnie.2021.03.016_bib0075","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","article-title":"Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B","volume":"25","author":"Price","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"10.1016\/j.remnie.2021.03.016_bib0080","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00259-010-1382-8","article-title":"Visual assessment of [(11)C]PIB PET in patients with cognitive impairment","volume":"37","author":"Suotunen","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.remnie.2021.03.016_bib0085","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","article-title":"Individualized quantification of brain \u03b2-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls","volume":"38","author":"Barthel","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.remnie.2021.03.016_bib0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Demen"},{"issue":"2","key":"10.1016\/j.remnie.2021.03.016_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2967\/jnumed.110.082057","article-title":"Early 11CPIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients","volume":"52","author":"Rostomian","year":"2011","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.remnie.2021.03.016_bib0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbadis.2011.11.006","article-title":"The use of PIB-PET as a dual pathological and functional biomarker in AD","volume":"1822","author":"Forsberg","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.remnie.2021.03.016_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","article-title":"Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases","volume":"14","author":"Daerr","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"February (2)","key":"10.1016\/j.remnie.2021.03.016_bib0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00259-018-4238-2","article-title":"Dual-phase [18F]florbetapir in frontotemporal dementia","volume":"46","author":"Asghar","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"September (9)","key":"10.1016\/j.remnie.2021.03.016_bib0115","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jalz.2019.05.010","article-title":"18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer\u2019s disease: validation against 15O-H2O PET","volume":"15","author":"Ottoy","year":"2019","journal-title":"Alzheimers Demen"},{"key":"10.1016\/j.remnie.2021.03.016_bib0120","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","article-title":"Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease","volume":"43","author":"Tiepolt","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.remnie.2021.03.016_bib0125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-011-2051-2","article-title":"Correlation of early-phase 18F-florbetapir (AV-45\/Amyvid) PET images to FDG images: preliminary studies","volume":"39","author":"Hsiao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2021.03.016_bib0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tics.2004.07.008","article-title":"Organization, development and function of complex brain networks","volume":"8","author":"Sporns","year":"2004","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.remnie.2021.03.016_bib0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tics.2010.04.004","article-title":"Large-scale brain networks in cognition: emerging methods and principles","volume":"14","author":"Bressler","year":"2010","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.remnie.2021.03.016_bib0140","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00259-009-1264-0","article-title":"EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2","volume":"36","author":"Varrone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2021.03.016_bib0145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12021-014-9235-4","article-title":"A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia","volume":"12","author":"Della Rosa","year":"2014","journal-title":"Neuroinformatics"},{"key":"10.1016\/j.remnie.2021.03.016_bib0150","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00429-019-01969-8","article-title":"Source-based morphometry: a decade of covarying structural brain patterns","volume":"224","author":"Gupta","year":"2019","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.remnie.2021.03.016_bib0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hbm.20540","article-title":"Source-based morphometry: the use of independent component analysis to identify gray matter differences with application to schizophrenia","volume":"30","author":"Xu","year":"2009","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.remnie.2021.03.016_bib0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/brain.2011.0015","article-title":"Source-based morphometry analysis of group differences in fractional anisotropy in schizophrenia","volume":"1","author":"Caprihan","year":"2011","journal-title":"Brain Connect"},{"key":"10.1016\/j.remnie.2021.03.016_bib0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/brain\/awv337","article-title":"Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant","volume":"139","author":"Steenwijk","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.remnie.2021.03.016_bib0170","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s11307-017-1052-3","article-title":"Source-based morphometry multivariate approach to analyze [123I]FP-CIT SPECT Imaging","volume":"19","author":"Premi","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.remnie.2021.03.016_bib0175","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/schbul\/sbu177","article-title":"Patterns of gray matter abnormalities in schizophrenia based on an international mega-analysis","volume":"41","author":"Gupta","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.remnie.2021.03.016_bib0180","article-title":"Grey matter changes in cognitively impaired Parkinson\u2019s disease patients","volume":"21","author":"Rektorova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.remnie.2021.03.016_bib0185","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","article-title":"Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury","volume":"47","author":"Bayer","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808921000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808921000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:44:10Z","timestamp":1762418650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808921000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2253808921000628"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2021.03.016","relation":{},"ISSN":["2253-8089"],"issn-type":[{"type":"print","value":"2253-8089"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between brain glucose metabolism (18F-FDG) and cerebral blood flow with amyloid tracers (18F-Florbetapir) in clinical routine: Preliminary evidences","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2021.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}